The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...